CD19 and benign prostatic hyperplasia: In the B cell panel, we have learned that IL-10 can be produced, which has the effect of reducing immune suppression against tumors and enhancing immune escape.[36,37] Based on this, it has been reported that IL-10 expression and the frequency of CD19+ IL-10+ B cells are higher in PC tissues than in benign prostatic hyperplasia, providing factual grounds for our pathological assessment of PC risk.[61] This will provide us with a certain factual basis for determining the risk factors of PC at the pathological level.